Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest HER2/neu Stories

2013-05-31 12:21:41

Studies Submitted to ASCO Demonstrate Immunogenic Superiority of AE37 Over All Other Peptide Cancer Vaccines WORCESTER, Mass. and TORONTO, May 31, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today highlighted advantages of its AE37 cancer vaccine and technology in the context of a positive cancer immunotherapy forecast recently issued by Citigroup analysts. The Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com)...

2013-05-31 08:24:39

Prognostic Information from Oncotype DX in Metastatic Breast Cancer Indicates Importance of Biology Revealed by the Test Across Continuum of the Disease REDWOOD CITY, Calif., May 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 10 studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the company's commitment to optimizing cancer treatment. New data include studies of the Oncotype DX®...

2013-05-30 08:28:12

-Array to Hold Conference Call to Discuss Collaboration on May 30 at 10 a.m. E.T.- SEATTLE and BOULDER, Colo., May 30, 2013 /PRNewswire/ -- Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor. HER2, also known as ErbB2, is a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers such...

2013-05-22 08:29:34

Studies show superiority of AE37 among peptide cancer vaccines WORCESTER, Mass. and TORONTO, May 22, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the annual meeting of the American Society of Clinical Oncology (ASCO)...

2013-05-21 12:27:14

Improvements in Efficacy Endpoints Including Disease Progression are Key Drivers for Prescribing in this Population, According to a New Report from Decision Resources BURLINGTON, Mass., May 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging agent on key efficacy endpoints, including overall survival and time to disease progression, has the most influence...

2013-05-21 08:28:18

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 - 4:30 PM. The presentation will...

2013-05-07 23:22:29

A new study published in The Oncologist shows targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer (MBC) patients significantly increased overall survival times. Durham, NC (PRWEB) May 07, 2013 A new study published in The Oncologist shows targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer (MBC) patients...

2013-04-23 18:47:52

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen´s secondary activities so that it might work on more aggressive breast cancer. The research, published in the journal EMBO Molecular Medicine, is a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease. This subtype has a...

2013-04-10 08:32:36

Study Presented at AACR 2013 Examines Bispecific Antibody in Combination with Paclitaxel and Trastuzumab CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was presented as part of the American...

2013-04-08 12:28:40

NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...